Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 318,282 Shares

Key Points

• Eric Venker, CEO of Roivant Sciences, sold a total of 318,282 shares at an average price of $17.05, totaling over $5.4 million, which decreased his ownership position by 17.46%.
• Following the recent sales, Venker still owns 1,504,959 shares of the company, valued at approximately $25.66 million.
• Roivant Sciences has a market cap of $11.79 billion and notable price targets from analysts range from $16.00 to $24.00, with a consensus rating of "Moderate Buy."

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 318,282 shares of the firm's stock in a transaction dated Thursday, October 16th. The stock was sold at an average price of $17.05, for a total transaction of $5,426,708.10. Following the completion of the transaction, the chief executive officer directly owned 1,504,959 shares in the company, valued at $25,659,550.95. This represents a 17.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Friday, October 17th, Eric Venker sold 118,418 shares of Roivant Sciences stock. The shares were sold at an average price of $17.06, for a total transaction of $2,020,211.08.
• On Wednesday, October 15th, Eric Venker sold 414,683 shares of Roivant Sciences stock. The shares were sold at an average price of $16.93, for a total transaction of $7,020,583.19.
• On Monday, October 13th, Eric Venker sold 20,727 shares of Roivant Sciences stock. The shares were sold at an average price of $16.25, for a total transaction of $336,813.75.
• On Thursday, October 9th, Eric Venker sold 104,940 shares of Roivant Sciences stock. The shares were sold at an average price of $16.30, for a total transaction of $1,710,522.00.
• On Wednesday, October 8th, Eric Venker sold 138,602 shares of Roivant Sciences stock. The shares were sold at an average price of $16.20, for a total transaction of $2,245,352.40.
• On Monday, October 6th, Eric Venker sold 171,396 shares of Roivant Sciences stock. The shares were sold at an average price of $16.34, for a total transaction of $2,800,610.64.
• On Tuesday, October 7th, Eric Venker sold 355,161 shares of Roivant Sciences stock. The shares were sold at an average price of $16.15, for a total transaction of $5,735,850.15.
• On Tuesday, September 23rd, Eric Venker sold 611,000 shares of Roivant Sciences stock. The shares were sold at an average price of $14.83, for a total transaction of $9,061,130.00.
• On Monday, September 22nd, Eric Venker sold 416,182 shares of Roivant Sciences stock. The shares were sold at an average price of $14.99, for a total transaction of $6,238,568.18.
• On Friday, September 19th, Eric Venker sold 683,818 shares of Roivant Sciences stock. The shares were sold at an average price of $14.95, for a total transaction of $10,223,079.10.

Roivant Sciences Price Performance

NASDAQ ROIV traded up $0.15 during trading on Friday, reaching $17.26. 8,793,524 shares of the company's stock traded hands, compared to its average volume of 7,509,870. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $17.33. The firm has a market cap of $11.79 billion, a price-to-earnings ratio of -24.66 and a beta of 1.20. The company's 50 day simple moving average is $13.97 and its two-hundred day simple moving average is $12.01.

Institutional Trading of Roivant Sciences

Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its stake in Roivant Sciences by 83.0% during the 1st quarter. GAMMA Investing LLC now owns 6,493 shares of the company's stock valued at $66,000 after acquiring an additional 2,945 shares during the period. Assenagon Asset Management S.A. acquired a new position in shares of Roivant Sciences in the 1st quarter valued at $570,000. Fifth Third Bancorp lifted its stake in shares of Roivant Sciences by 59.3% in the 1st quarter. Fifth Third Bancorp now owns 5,118 shares of the company's stock valued at $52,000 after purchasing an additional 1,905 shares during the period. Penn Davis Mcfarland Inc. lifted its stake in shares of Roivant Sciences by 3.5% in the 1st quarter. Penn Davis Mcfarland Inc. now owns 1,707,232 shares of the company's stock valued at $17,226,000 after purchasing an additional 58,206 shares during the period. Finally, GF Fund Management CO. LTD. lifted its stake in shares of Roivant Sciences by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 18,641 shares of the company's stock valued at $188,000 after purchasing an additional 3,356 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Bank of America raised their price target on shares of Roivant Sciences from $12.00 to $16.50 and gave the company a "neutral" rating in a report on Thursday, September 18th. Citigroup assumed coverage on shares of Roivant Sciences in a report on Tuesday, September 2nd. They issued a "buy" rating and a $16.00 price target on the stock. The Goldman Sachs Group raised their price target on shares of Roivant Sciences from $20.00 to $24.00 and gave the company a "buy" rating in a report on Thursday, September 18th. Weiss Ratings restated a "sell (d+)" rating on shares of Roivant Sciences in a report on Wednesday, October 8th. Finally, Jefferies Financial Group raised their price target on shares of Roivant Sciences from $18.00 to $20.00 and gave the company a "buy" rating in a report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $19.94.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.